Exousia Pro Business Summary

Exousia Pro, Inc. (MAJI) operates as a clinical-stage biotechnology company that has transitioned into a vertically integrated healthcare ecosystem through its three primary business segments: Exousia Health (telehealth), Exousia AI (biotech R&D), and its nutraceutical division. The company generates revenue through a diversified model comprising monthly recurring subscription fees from its telehealth patient base, performance-based earnings—specifically capturing 10% of hospital prescription savings over four-year periods—and direct-to-patient sales of proprietary exosomal products like Maxasome™. By acquiring established telehealth platforms, MAJI leverages a built-in provider network to market its advanced cancer screening tests and clinical supplements, significantly reducing customer acquisition costs (CAC) compared to traditional biotech peers. In the competitive landscape, MAJI contends with telehealth giants like Hims & Hers and Teladoc Health, as well as exosome-focused biotechs such as Capricor Therapeutics and Evox Therapeutics; however, MAJI distinguishes itself by owning the end-to-end distribution channel, bridging the gap between clinical innovation and direct commercial access. The leadership team is spearheaded by CEO Mike Sheikh and President Matt Dwyer, who have orchestrated the company’s strategic realignment from its former identity as Marijuana, Inc. Sheikh brings over 20 years of experience as a biotech analyst and executive specializing in oncology and exosome-based delivery systems, while Dwyer serves as the primary architect of the company’s aggressive acquisition strategy and its relationship with the SEC-reporting subsidiary Lamy (LMMY). The executive team is supported by a strategic partnership with Ludwig Enterprises, Inc., a major shareholder that facilitated the acquisition of the core Exousia AI technology. This leadership group has focused on a "non-dilutive" growth roadmap, utilizing the LMMY platform to raise expansion capital while maintaining majority control of the underlying intellectual property for glioblastoma and other therapeutic applications.